May 15, 2025

Visual Difficulty, Falls, and Mortality

Recurrent falls were associated with a nearly 50% increased hazard of mortality.

Conexiant

May 05, 2025

PDS Updates Continue to Reduce Treatment Burden for Patients with nAMD, DME, and DR

These types of improvements are relatively common after initial approval and are the result of optimization as surgical techniques and knowledge evolve.

Conexiant

April 27, 2025

How to Increase Volume in the Space You Have

It's all about flow, says consultant Larry R. Brooks.

Ophthalmology Management

April 24, 2025

FDA Rejects Extended Dosing Intervals for Eylea HD

The agency did not agree with Regeneron’s proposal to add dosing intervals greater than every 16 weeks, the maximum interval currently indicated for aflibercept 8 mg injections.

Retinal Physician

February 26, 2025

Integration of Vision Services Remains an Unmet Need in FQHCs

Telemedicine, funding, and provider partnerships can help, researchers say.

Conexiant

January 16, 2025

LA County Fires Prompt Business Recovery Centers to Open

"Business owners can meet face-to-face with specialists to apply for disaster loans and access a wide range of resources to guide them through their recovery."

Optometric Management

April 02, 2025

GLP-1 RAs Evaluated for Long-Term Risk of NAION in Patients With Diabetes

Researchers’ subgroup analyses provide data on increased risks according to timepoint, demographics, and comorbidities.

Conexiant

July 03, 2024

Semaglutide Linked to Vision-Threatening Eye Disorder

New study finds that 8.9% of type 2 diabetes patients taking semaglutide experienced NAION, compared to 1.8% of those on non-GLP-1 diabetes drugs.

Reuters

January 24, 2025

Once-Weekly Semaglutide Doubles Risk of NAION in T2D

“After the introduction of once-weekly semaglutide in Denmark in November 2018, the annual number of first-time NAION episodes reached an all-time high for the years 2019 through 2023.”

Conexiant